Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Total Brain Limited
  6. News
  7. Summary
    TTB   AU0000032435

TOTAL BRAIN LIMITED

(TTB)
  Report
Delayed Australian Stock Exchange  -  07:39 2022-10-03 pm EDT
0.0390 AUD    0.00%
08/30Total Brain Limited Reports Earnings Results for the Full Year Ended June 30, 2022
CI
08/05Total Brain Agrees to Salell Business for $10 Million
MT
08/05SonderMind Inc. entered into an agreement to acquire Assets of Total Brain Limited for $10 million.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to Develop New Drugs for Neurological Disorders

05/26/2022 | 09:15am EDT

VeriSIM Life announced that it has entered into a partnership agreement with Total Brain to create breakthrough neurodata-driven actionable insights for developing novel drugs to treat a wide range of neurological disorders. The partnership will pioneer the integration of Total Brain's proprietary mental health and brain performance database with VeriSIM Life's BIOiSIM™ AI-enabled drug development decision engine to enable new psychiatric and neurological therapies. The Total Brain platform helps more than one million individuals improve overall mental health and brain performance using several semi-quantitative functional methods.

The company's data sets represent the larger standardized brain database encompassing human electrical brain function, brain structure and blood flow, inclusive of full genetic assessments. With this partnership, the BIOiSIM platform will utilize its Translational Index to discover novel drug candidates with other capabilities such as: Evaluate efficacy and side effects of existing drugs and novel drug candidates used to treat various neurological conditions in specific patient subpopulations with differing genetic, biomarker and demographic profiles, Develop highly differentiated patient stratification strategies, Help biotechnology companies develop genetics prediction products related to neurological diseases, Develop companion diagnostics tracking essential biomarker data during the development of new drugs treating neurological diseases.


© S&P Capital IQ 2022
All news about TOTAL BRAIN LIMITED
08/30Total Brain Limited Reports Earnings Results for the Full Year Ended June 30, 2022
CI
08/05Total Brain Agrees to Salell Business for $10 Million
MT
08/05SonderMind Inc. entered into an agreement to acquire Assets of Total Brain Limited for ..
CI
06/02Total Brain : Application for quotation of securities - TTB
PU
06/02Total Brain Limited announced that it expects to receive AUD 0.0396 million in funding
CI
05/26VeriSIM Life and Total Brain Announce Strategic Collaboration Agreement Applying AI to ..
CI
05/20Total Brain : Dr. Evian Gordon, Chief Medical Officer, Total Brain, to Address the Role of..
PU
05/10Total Brain Limited Announces 5-Year Extension of AARP Contract
CI
05/03Transcript : Total Brain Limited, Q3 2022 Earnings Call, May 04, 2022
CI
04/10Total Brain : Notification regarding unquoted securities - TTB
PU
More news
Financials
Sales 2022 9,80 M 6,37 M 6,37 M
Net income 2022 -4,00 M -2,60 M -2,60 M
Net Debt 2022 2,36 M 1,53 M 1,53 M
P/E ratio 2022 -1,36x
Yield 2022 -
Capitalization 5,22 M 3,39 M 3,39 M
EV / Sales 2022 0,77x
EV / Sales 2023 0,51x
Nbr of Employees 29
Free-Float 59,3%
Chart TOTAL BRAIN LIMITED
Duration : Period :
Total Brain Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TOTAL BRAIN LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,04
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Matthew Mund Chief Executive & Operating Officer
Evian Gordon Executive Chairman & Chief Medical Officer
Donna Palmer Chief Science Officer
Matthew Morgan Non-Executive Director
David Torrible Non-Executive Director